Clinical Trials Logo
  1. Home
  2. Rosacea
  3. NCT02576847
  4. Details
NCT02576847 Clinical Trial

Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel

Rosacea Clinical Trial

Official title:
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02576847
Other study ID # CLS001-CO-PR-006
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 2015
Est. completion date February 8, 2018

Study information
Verified date July 2022
Source Maruho Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the long-term safety of once-daily application of Omiganan topical gel in subjects with severe papulopustular rosacea.

Recruitment information / eligibility
Status Completed
Enrollment 307
Est. completion date February 8, 2018
Est. primary completion date July 14, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Healthy, male and nonpregnant female subjects, 18 years of age or older. 2. A diagnosis of severe papulopustular rosacea using the Investigator Global Assessment grading scale at baseline 3. Subjects with the presence of telangiectasia at Baseline 4. Subjects with the presence of facial erythema associated with their rosacea at Baseline Exclusion Criteria: 1. Subjects with steroid rosacea or subtype 3 (phymatous rosacea). 2. Subjects with nodular rosacea 3. Standard exclusion criteria.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Omiganan
Topical gel

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Maruho Co., Ltd.

Countries where clinical trial is conducted

United States,  Australia,  Canada,  France,  Netherlands,  New Zealand,  Sweden,  United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of Subjects With 1 or More Treatment-related Treatment-Emergent Adverse Events Number of subjects with 1 or more treatment-related Treatment-Emergent Adverse Events Up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT05597462 - Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks Phase 1
Completed NCT02601963 - Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea Phase 2
Completed NCT02249065 - Mirvaso in Use Study Phase 4
Completed NCT02292797 - Assessment of the Rosacea Prevalence in the General Population N/A
Completed NCT01659853 - Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea Phase 3
Completed NCT01426269 - Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo Phase 4
Completed NCT00991198 - The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage Phase 2
Terminated NCT04336163 - Skin Imaging to Inform Laser Treatments N/A
Recruiting NCT04108897 - Analysis of the Microbiome in Rosacea Early Phase 1
Completed NCT03872050 - Deep Phenotyping of Rosacea and Migraine
Recruiting NCT06033352 - Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea Phase 2
Completed NCT03263273 - Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea Phase 2
Completed NCT04508660 - CGB-400 for the Reduction of Facial Redness Phase 1
Completed NCT04508205 - CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes Phase 1
Completed NCT05094700 - A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants N/A
Active, not recruiting NCT03211585 - EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA N/A
Completed NCT02637232 - Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
Completed NCT02576860 - Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Phase 3
Completed NCT02583009 - A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea Phase 2
Completed NCT01993446 - A Safety and Efficacy Study of DRM02 in Subjects With Rosacea Phase 2